Industry Reports
Thunderbolt Pharma, Inc , Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.
Baxalta Incorporated , Velocity Pharmaceutical Development, LLC and Astellas Pharma Inc announced that Thunderbolt, Inc., a company established by Vitesse Biologics, acquired all rights...
Press Releases
Daiichi Sankyo Launches Antiplatelet Agent Efient® Tablets 20mg
Daiichi Sankyo Company, Limited announced that it has launched the antiplatelet agent Efient® Tablets 20mg (JAN: Prasugrel Hydrochloride; approval to market: January 20, 2016;...
Press Releases
EISAI To Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) As Adjunctive Therapy For Partial-Onset And Generalized Tonic-Clonic Seizures In Japan
Eisai Co Ltd announced that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa® Tablets 2 mg and 4 mg (perampanel hydrate) as an...
Press Releases
Novo Nordisk IDegLira receives positive 16-0 vote in favour of approval from FDA
Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the...
Press Releases
Bayer Comments on Monsanto’s Statement Regarding Proposed Transaction
Bayer announced that it looks forward to engaging in constructive discussions with Monsanto regarding the proposed transaction. Bayer reiterated that its USD 122 per...
Industry Reports
Merck Co Inc Announces Third-Quarter 2016 Dividend
Merck announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third...
Press Releases
FDA Expands Invokamet Label to Include First-Line Treatment of with type 2 diabetes
Janssen Pharmaceuticals, Inc announced the U.S. FDA has approved INVOKAMET®, a fixed-dose combination therapy of INVOKANA® (canagliflozin) and metformin hydrochloride, for first-line treatment of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read